Health Affairs, 25, no. 2 (2006): 348-356
doi: 10.1377/hlthaff.25.2.348
© 2006 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Online Appendix
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (2)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Bishai, D.
* Articles by Wigton, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Bishai, D.
* Articles by Wigton, A.
Related Collections
* Access To Care
* Health Promotion/Disease Prevention
* International Issues
* Business Of Health
* Public Health
* Research And Technology
* Health Spending
* Politics
* Consumer Issues
* Vaccines

Drugs/Vaccines

The Costs Of Scaling Up Vaccination In The World’s Poorest Countries

David Bishai, Michael McQuestion, Rochika Chaudhry and Alyssa Wigton

We examine the relationship between country-level average costs and coverage levels for diptheria-pertussis-tetanus (DTP) vaccines. Coverage data are from the World Health Organization, and cost data are from financial sustainability plans filed with the Global Alliance for Vaccines and Immunization (GAVI) by forty countries from 2000 to 2003. In this data set, average costs are lower for countries that vaccinate more children. At the highest numbers of covered children, there was no trend toward higher average costs. Vaccine programs in this set of poor countries have not yet scaled up to the point at which diminishing marginal returns are observed.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
J Public Health (Oxf)Home page
E. I. Broughton
Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis
J Public Health, December 1, 2007; 29(4): 441 - 448.
[Abstract] [Full Text] [PDF]